MESO 11.82 (-0.67%)
US5907171046BiotechnologyBiotechnology

Mesoblast (MESO) Stock Highlights

11.82 | -0.67%
2025-04-03 04:13:15
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

Statistics

Range Today
11.74 12.14
Volume Today 167.1K
Range 1 Year
4.6 22
Volume 1 Year 79.41M
Range 3 Year
1.61 22
Volume 3 Year 250.79M
Range 10 Year
1.61 42.56
Volume 10 Year 412.97M

Highlights

Market Capitalization 1.56B (small)
Floating Shares 652.57M
Current Price 11.82
Price To Earnings -13.82
Price To Revenue 2.72K
Price To Book 30.27
Earnings Per Share -0.94
Payout Ratio 0%

Performance

Latest -0.67%
1 Month -25.19%
3 Months -43.2%
6 Months +40.88%
1 Year +95.7%
3 Years +36.49%
5 Years +26.28%
10 Years -56.29%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.